Oridonin Relieves Angiotensin II-Induced Cardiac Remodeling via Inhibiting GSDMD-Mediated Inflammation
Open Access
- 14 March 2022
- journal article
- research article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2022, 1-17
Abstract
Myocardial remodeling is one of the main lesions in the late stage of chronic heart failure and seriously affects the prognosis of patients. Continuous activation of the renin-angiotensin-aldosterone system (RAAS) contributes to the development of myocardial remodeling greatly, and angiotensin II (Ang II), its main constituent, can directly lead to cardiac remodeling through an inflammatory response and oxidative stress. Since Ang II-induced myocardial remodeling is closely related to inflammation, we tried to explore whether the anti-inflammatory drug oridonin (Ori) can reverse this process and its possible mechanism. Our study investigated that hypertrophy and fibrosis can be induced after being treated with Ang II in cardiomyocytes (H9c2 cells and primary rat cardiomyocytes) and C57BL/6J mice. The anti-inflammatory drug oridonin could effectively attenuate the degree of cardiac remodeling both in vivo and vitro by inhibiting GSDMD, a key protein of intracellular inflammation which can further activate kinds of inflammation factors such as IL-1β and IL-18. We illustrated that oridonin reversed cardiac remodeling by inhibiting the process of inflammatory signaling through GSDMD. After inhibiting the expression of GSDMD in cardiomyocytes by siRNA, it was found that Ang II-induced hypertrophy was attenuated. These results suggest that oridonin is proved to be a potential protective drug against GSDMD-mediated inflammation and myocardial remodeling.Keywords
Funding Information
- Key Research and Development Program of Zhejiang (2019C03012, 82003750, LQ21H020009, LQ19H020004)
- National Natural Science Foundation of China (2019C03012, 82003750, LQ21H020009, LQ19H020004)
- Natural Science Foundation of Zhejiang Province (2019C03012, 82003750, LQ21H020009, LQ19H020004)
This publication has 44 references indexed in Scilit:
- Interferon-γ Signaling Inhibition Ameliorates Angiotensin II–Induced Cardiac DamageHypertension, 2012
- Activation of the renal Na + :Cl − cotransporter by angiotensin II is a WNK4-dependent processProceedings of the National Academy of Sciences, 2012
- New Take on the Role of Angiotensin II in Cardiac Hypertrophy and FibrosisHypertension, 2011
- Cardiac-Specific Activation of Angiotensin II Type 1 Receptor–Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin II–Infused MiceHypertension, 2010
- Interferon-γ and the Interferon-Inducible Chemokine CXCL10 Protect Against Aneurysm Formation and RuptureCirculation, 2009
- Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?Hypertension, 2007
- Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin IICardiovascular Research, 2005
- Requirement of Nuclear Factor-κB in Angiotensin II– and Isoproterenol-Induced Cardiac Hypertrophy In VivoCirculation, 2005
- Oridonin, a diterpenoid purified fromRabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathwaysMolecular Cancer Therapeutics, 2005
- Activation of MAPKs by Angiotensin II in Vascular Smooth Muscle CellsJournal of Biological Chemistry, 2001